Cizzle Biotechnology to offer early lung cancer tech throughout the USA (VIDEO)

Cizzle Biotechnology Holdings plc (LON:CIZ), the UK based diagnostics developer, has announced that it has signed an extension to its exclusive licensing and partnership agreement for the USA and Canada, executed on 21 October 2024, with Cizzle

Cizzle Biotechnology Holdings plc (LON:CIZ), the UK based diagnostics developer, has announced that it has today signed an exclusive licensing and partnership agreement for its proprietary CIZ1B biomarker test to help detect early-stage lung cancer, throughout the USA and

Cizzle Biotechnology Holdings plc (LON:CIZ), the UK based diagnostics company focused on developing a cost-effective biomarker test to help detect early-stage lung cancer, has announced that it has been selected by the Moffitt Cancer Center, the number

Cizzle Biotechnology Holdings plc (LON:CIZ), the UK-based diagnostics company focused on developing a cost effective biomarker test to help detect early-stage lung cancer, has announced a strategic agreement with BBI Solutions, the world’s largest independent producer of

Cizzle Biotechnology Holdings plc (LON:CIZ), the UK based diagnostics developer, has announced the publication of the Company’s Annual Report and Financial Statements for the year ended 31 December 2023: Cizzle Biotechnoloy is developing a blood test

Cizzle Biotechnology Holdings plc (LON:CIZ), the UK based diagnostics developer, has announced that it has signed a non-binding Memorandum of Understanding for a strategic and exclusive licensing agreement to develop and offer its proprietary test for the CIZ1B

Cizzle Biotechnology Holdings plc (LON:CIZ), the UK based diagnostics developer, has announced a further update regarding the Company’s put option to sell its 5% economic interest and royalty sharing agreement in the AZD 1656 asset to treat

Bio-Techne Corporation (NASDAQ: TECH) and Cizzle Biotechnology Holdings plc (LON:CIZ), the UK-based diagnostics developer, have announced recent progress evaluating specific monoclonal antibodies for Cizzle’s CIZ1B cancer biomarker. Cizzle has successfully completed an evaluation programme aimed at assessing the feasibility of

Cizzle Biotechnology Holdings plc (LON:CIZ), the UK based diagnostics developer, has announced a further update regarding the Company’s put option to sell its 5% economic interest and royalty sharing agreement in the AZD 1656 asset to treat

Cizzle Biotechnology Holdings plc (LON:CIZ), the UK based diagnostics developer, has announced an expansion of its current research programme with the University of York to develop its CIZ1B biomarker technology for early stage cancer diagnosis, and other potential

Cizzle Biotechnology (LON:CIZ), the UK-based diagnostics developer, has announced that it has conditionally raised gross proceeds of £350,000 (before expenses of £17,500) by way of the issue of 16,666,667 new Ordinary Shares at 2.1p per share with